Parkinson’s Impulse Disorders links to Drugs

According to a new study untreated Parkinson's disease patients are no more likely to have impulse control disorders like gambling and impulse buying, than people without the disease. A team of researchers from the Perelman School of Medicine at the University of Pennsylvania in the US make these findings.

When looking at newly diagnosed Parkinson's patients who had yet to be treated with drugs targeting the dopamine system, there is no dissimilarity in impulsivity than what found in healthy people without the disease. Researchers suggests their evidence is the strongest so far to suggest it is the drugs used to treat Parkinson's that increase impulse control disorders in patients with the disease.

Impulse control disorders are more serious than infrequently not being able to resist that last piece of cake, or sometimes breaking a resolution not to buy any more shoes this year. People with impulse control disorders may or may not plan the spontaneous actions, which usually satisfy short term wishes. But on the whole, most people with the condition feel they are losing control of their lives and find their disorders highly painful.

Study proves 1 in 5 Parkinson's disease patients have impulse control disorder symptoms. However what this latest study appears to show, is that it is not the disease itself that increases the risk of gambling, shopping, or other impulsivity symptoms. The impulse control measure was particularly developed and validated for use with Parkinson's disease.

Smoking Establish To Worsen Hangover Symptoms-US

For anybody who has had one too a lot of drinks on a night out, a dry mouth, thumping head and nausea will be all too familiar symptoms the morning after. But now scientists say your hangover could feel a whole lot worse if you smoke as well. A team of scientists starting Brown University found this effect wasn't because smokers drank additional.

Now day’s team controlled for other factors as well, such as whether young students reported drugs use in the long-ago year. Smoking itself was connected to an increased risk of overshadow compared with not smoking at all. But according to Cancer Research, tobacco smoke contains the chemical acetaldehyde which is also bent in your body tissues when you drink alcohol and is responsible for numerous nasty hangover symptoms.

By Using Alcohol & Drugs The Disadvantages

In the world so loads of of people use alcohol and drugs for a number of reasons, but there are disadvantages from drug and alcohol use. If you think you might need to stop using alcohol or drugs due to -ve effects, consider seeing a analyst that specializes in substance-abuse issues or presence a self-help group like Alcoholics Anonymous or Narcotics Anonymous.

Addiction

·         Use of alcohol and numerous drugs can lead to habit. Often, addiction occurs at least in part because these substances trigger a release of dopamine in the human brain, which feels good. A person begins to desire more and more alcohol or drugs to get that good feeling. Once someone becomes obsessed, his life begins to spin around alcohol or drugs and he cannot stop using them. Symptoms of opiate withdrawal contain anxiety, muscle pain, nausea and vomiting. Symptoms of alcohol removal include shakiness, nausea, hallucinations and seizures.

Health Consequences

·      Alcohol and drug use has many harmful health consequences. For case, excessive alcohol use can cause injure to the liver and pancreas, ulcers, diabetes and heart problems. Cocaine use can cause holes in the nasal cartilage, lung damage, ulcers, kidney crash and heart attacks.

Mood Change

    Alcohol and drugs cause temper changes. Some people like some of the mood changes. For instance, they may feel life happy or even euphoric. They may feel tranquil. Alcohol and drugs can cause disagreeable mood changes, too, though. Alcohol and many drugs can lead to gloominess. Some drugs reason anxiety, irritability or even paranoia. These mood changes can create problems in associations and on the job.

Rare diseases in the attention

Rare diseases are likely to get more attention currently that an international consortium of patient advocacy groups and research funders has vowed to deliver 200 fresh therapies by 2020. For people with these diseases, such notice must seem long overdue. Drug companies now don’t have much incentive to expand drugs for diseases that affect fewer than 200,000 people, but almost 7,000 rare diseases exist disturbing a total of about 25 million Americans. Many are caused by mutations in a gene. The National Institutes of Health is opening a center in the fall to interpret research findings in genetics to usable therapies, the Associated Press reports.

The NIH previously has grant programs to spur research in rare diseases. The NIH's Therapeutics for Rare and Neglected Diseases plan has a pipeline of projects. Its pilot projects offer a glimpse into several of the diseases that, though rare, can nonetheless have incapacitating consequences. Schistosomiasis: Infection begins when a parasitic worm approved by freshwater snails penetrate the skin and lays eggs in blood vessels. First come rashes, then fever and chills, followed by liver and other organ injure over time. Researchers just decoded the genomes of two schistosomiasis-causing parasites, which may allow researchers to get ways to inhibit the parasites’ growth. About 200 million people worldwide have the disease, and 280,000 die from it every year.

Niemann-Pick Type C: In this condition, fatty deposits collect in the spleen, liver, lungs, bone marrow and brain. Type A, the most common, is fatal in infants. Type C can show early in life or in young adulthood; it causes brain damage and ultimately can change walking, swallowing, seeing and hearing. Only about 500 children in the world are recognized to have Type C. Researchers have found two genes that can give to Type C and Type D, but progress is slow. Hereditary inclusion body myopathy: Usually starting in young adulthood, the disease causes muscle wasting, foremost to severe disability in 10-20 years. A clinical trial in 2006 found mild benefits from intravenous immune globulin, fundamentally antibodies from blood plasma. A small gene therapy trial is happening, and stem cell therapy are being considered.

Blood Pressure Drugs can Help Heart Patients Without Hypertension

In people with heart disease, the use of blood pressure lowering medications can be useful, even in those who do not have high blood pressure, new research suggest. The study establish that when people without high blood pressure were given blood pressure drugs, their risk of congestive heart failure, stroke, all-cause humanity and a combination of cardiovascular disease outcomes were decreased. "If someone has had a previous heart attack or other cardiovascular event, and their blood pressure is in the usual range, they are still at risk of future cardiovascular events.

There may be an further benefit to giving an anti-hypertensive medication to these folks," said study author Angela M. Thompson, a doctoral research fellow in the department of epidemiology at Tulane University School of Public Health. "Current treatment suggestion advise treatment when the blood pressure is over 140/90 mm/Hg, but our study shows that you can get benefits even when the blood pressure is below that," Thompson explained. In information, the risk for cardiovascular disease begins at 115 mm/Hg of systolic pressure, according to background information in the study.

In addition, in adults 55 years and older, the lifetime risk of rising hypertension is more than 90 percent, the study noted. The study, which was funded by Tulane University and the National Institutes of Health, was published in the March 2 matter of the Journal of the American Medical Association. Cardiovascular disease is the foremost cause of death in the United States, according to background information in the study. About 54 percent of strokes and 46 percent of heart disease cases occur in people who have blood pressure levels in the usual range, the study reported.

Stem cell therapy for macular collapse

About 10 million Americans suffer several degree of vision loss cause by age-related macular degeneration, and that figure is predictable to grow as more baby boomers become senior citizens. There is no cure for the disease, but last week the U.S. Food and Drug Administration give a green light to an abnormal clinical trial that seeks to restore patients' view by employing human embryonic stem cells. None of the stem cells will be inject into patients; instead, they are grown into a different kind of cell that will be deliver to the back of the eye, where the retina is injured by the disease. The hope is that the cells will help mend the damaged retinal tissue.

The company behind the test, Santa Monica base superior Cell Technology Inc., developed the therapy to treat Stargardt's macular dystrophy, a rare childhood account of macular degeneration that affect about 1 in 10,000 kids. The FDA gave the company authorization to test the therapy in Stargardt's patients in November. However, if they work, the cells would have a much larger result as a treatment for age connected macular degeneration.

Another remedies seen as risk to young

Alternative remedy can have dangerous, and maybe fatal, side effects, particularly for vulnerable groups like children, Australian health expert say. Researchers say parents occasionally think alternative treatments are "more natural" with less side effects than conservative drugs, but children given option remedies can have unfavorable reactions, a study print in the journal Archives of Disease in Childhood said.

In almost two thirds of 39 cases in a study of incidents connecting children and exchange remedies by the Australian Pediatric Surveillance Unit between 2001 and 2003, the side belongings were rated as severe, life threatening or fatal. The incident concerned children ranging from babies to 16-year-olds. In 30 cases, the problem were "probably or definitely" related to matching medicine, and in 17 cases the patients were measured to have been harmed by a failure to administer conservative medicines, the study said.

"Many of the adverse actions associated with failure to use conventional medicine resulted from the family's belief in matching and alternative medicine and determination to use it although medical advice," the study author from the Royal Children's Hospital in Melbourne said. "Children don't take decisions themselves about their treatment; very often it is their parents, and parents can be mistaken by the 50 million option medicine websites," says Edzard Ernst, Professor of balancing Medicine at Exeter University in the United Kingdom.

Gilead Ends Trial of Novel Drug for Rare Lung Disease on Lack of effectiveness

Gilead Sciences Inc., the world’s major maker of AIDS drugs, said it is stopping a late stage study of an investigational lung disease therapy because it did not help patients with the state, idiopathic pulmonary fibrosis. The drug, ambrisentan, was in the last stage of testing usually necessary for U.S. approval, the Foster City, California- based company said in a report today. The decision to halt the study followed an interim study of data by a monitoring committee and the company’s review, according to the report.

Gilead said on Dec. 20 that it had decided to obtain Arresto Biosciences Inc., of Palo Alto, California, for $225 million. Arresto’s lead investigational drug is a monoclonal antibody being tested for cancer and idiopathic pulmonary fibrosis, the similar fatal lung disease that Gilead’s currently canceled study for ambrisentan was targeting. “Gilead is conduct a thorough review of the data and will converse the full consequences of this analysis to the medical community when they are accessible,” Gilead said in the statement.

Nathan Kaiser, a Gilead spokesman, said there is no association between the decision to stop the ambrisentan study and the company’s contract with Arresto. “Gilead was just conversant of the results of the data monitor committee this week,” Kaiser said in a telephone interview today. Ambrisentan conventional U.S. approval in 2007 as a treatment for pulmonary arterial hypertension, a tapering of the artery that causes smallness of breath and heart failure. It is market under the brand name Letairis. Gilead share fell 2 percent to $35.60 at 6:07 p.m. New York time in extensive trading on the Nasdaq Stock Market after finishing down 22 cents to $36.34.

useful links : transport rankings  

Diabetes Drug can treat Alzheimer's Disease

German scientists say a drug taken to treat type-2 diabetes may be efficient against Alzheimer’s disease. The researchers said the drug metformin counteracts change of the cell structure protein known as Tau in mice models. These cell structure changes are a important cause of the development of Alzheimer’s, the researchers said in a statement. The scientist were from the German Center for Neurodegenerative Disease, the University of Dundee and the Max Planck-Institute for Molecular Genetics.

During their research, the scientists also said they exposed the molecular mechanism of metformin. “If we can prove that metformin shows also an "effect in humans, it is certainly a good applicant for an efficient therapy on Alzheimer’s disease, Sybille Kraub, from the Center for Neurodegenerative Diseases, said in a report. The researchers said Alzheimer’s disease occur when neurons in the brain die, which lead to cognitive injury. Also, it is characterized by the configuration of Tau protein deposits in nerve cells.

Dr. Anne Corbett, research infrastructure manager for the Alzheimer’s Society, said the study offered some hope of a new and efficient drug treatment for the disease, but further research is needed to understand the link between Alzheimer’s and diabetes. “Previous research has recommended that metformin decrease the risk of dementia in diabetic people, and this study give some understanding of why this might be,” Corbett said in a statement. “'A million more people are set to expand dementia in the next 10 years. It is significant that people maintain a healthy lifestyle in order to decrease their risk and that larger investment in dementia research is made to more our understanding of the condition.”

useful links : transport rankings  

Heavy Alcohol Consumption May enlarge HIV Disease Progression

A new review of many studies has found some evidence linking heavy alcohol use to accelerated HIV disease progression. In particular, alcohol use influences how dependably people take their medication, which can affect HIV progression. However, it is still unclear whether alcohol affect sequence independently of antiretroviral adherence. “There is strong evidence that alcohol use interferes with antiretroviral therapy adherence. The more a person drinks alcohol, the extra medication he/she misses,” said Professors Judith Hahn and Jeffrey Samet, the authors of the appraisal, in correspondence with The AIDS Beacon.

“Suboptimal obedience to these medications can cause HIV to become opposed to and for the treatment regimen to fail,” they added. However, whether alcohol affects disease progression separately of missed antiretroviral drug doses is more controversial. Scientists have extensive speculated that alcohol and drug use affect the rate of HIV progression. Alcohol is known to have oppressive effects on the immune system, and illegal drug use has been linked to faster progression. However, the role of alcohol in HIV progression has remained elusive. “While many studies conduct in the early 1990s found no link between alcohol use and HIV disease progression, more recent studies have recommended that there is such a link,” said the authors.

To better recognize the connection between alcohol and disease progression, the authors of the review examine a number of studies from before and after the arrival of antiretroviral therapy, as well as animal studies where alcohol use was extra controlled. Results show that prior to the advent of highly active antiretroviral therapy (HAART), studies found no association between heavy alcohol consumption and HIV disease progression. However, more fresh studies from the post-HAART era have been inconclusive. Three of the six studies from the post-HAART era included in the review established an association between heavy alcohol use and at least one measure of HIV disease series, such as higher viral load, lower CD4 count, opportunistic infections, or death.

useful links : transport rankings  

WHO Outlines Strategy to Combat deserted Tropical Diseases

The international pharmaceutical company GlaxoSmithKline publicize October 14 that it will donate 400 million more tablets for the treatment of intestinal worms in children. This comes as the World Health Organization is calling on drug companies to donate more tablets to help to eradicate tropical diseases. The WHO says in a latest report that one billion people in the world's poorest countries are chronically ill from tropical diseases that receive little notice from drug manufacturers and health organizations.

The diseases leishmanaisis, chagas, dengue and 14 others are unknown to several people in developed countries, or are thought to have been eradicated long ago. But the World Health Organization says they cause massive, hidden affliction that keeps millions of people in poverty. And the WHO is calling on governments, donors and pharmaceutical companies to help decrease those numbers significantly. Dr. Peter Hotez is a specialist in tropical diseases. He says that these parasitic diseases are rampant even though they are simply treatable.

"The neglected tropical disease program of USAID, which is also funded through global health initiative, in some cases can lead to the removal of some very important neglected tropical diseases such as lymphatic filariasis, perhaps river blindness and leprosy," he said. Dr. Hotez says that these diseases can often be treating with a single pill. But there is often is no funding for proven and cheap treatments. "Out of 10 billion exhausted annually, only 65 million, less than one percent, is spent on deserted tropical diseases. We have to begin bringing that up because these conditions are just as significant and we can do something about them through mass drug administration." 

useful links : transport rankings

FDA may control anemia drug use for kidney disease

The Food and Drug Administration is considering new limits on widely used anemia drugs that emerge to double the risk of stroke in patients with kidney disease. The FDA posted its safety appraisal of the three blood boosting medications from Amgen Inc. on Thursday, focusing on their use in patients with chronic kidney disease who are not yet sick sufficient to receive dialysis. The medicines Procrit, Aranesp and Epogen are multibillion dollar sellers because of their capability to boost oxygen-carrying red blood cells, reducing the require for painful blood transfusions. But sales have fallen stridently since 2007, when the FDA added the first of many safety warnings to the drugs, based on evidence they can cause tumor enlargement and hasten death in cancer patients. The drugs are no longer used in patients with several types of cancers.

Anemia, which causes weakness and smallness of breath, is a side result of chemotherapy and kidney failure. Now the FDA is review a study published last year that show kidney disease patients taking Aranesp were twice as likely to knowledge stroke compare with those taking a dummy treatment. The goal of the study was to show that the drug could avoid heart attack, stroke and other heart related problems, as had been assumed for years. But FDA reviewers, using the chemical name for Aranesp, said in their posting that the "proof raises considerable doubt about the safety and desirability of using darbepoetin in this manner."

Amgen has argued that its drugs should carry on to be used because they help avoid blood transfusions, which carry their own risks. But the FDA's scientists point out that 15 percent of patients who took the company's drug still wanted transfusions, compared with 25 percent of those taking a placebo treatment. "Treatment did not eliminate the risk of need transfusions," states the FDA review. On Monday the agency will ask a panel of outside expert to review the data and create recommendations on how to safely use the drugs. Panelists could recommend bolstered warning labels, extra studies or lower doses of the drugs. The FDA is not necessary to follow the group's advice, although it often does.

useful links : transport rankings

Chicago among sites for foremost study on Parkinson's disease

About 1 million American people have Parkinson's disease, a progressive disorder of the central nervous system. There are treatments that can temporarily improve the symptoms, but there is not a cure. Now, a five-year study is being kick off at 18 research sites around the world, including one in Chicago, to speed up the growth of treatments to slow or stop the progression of this disease. The Parkinson's Progression Markers scheme, a study funded with $40 million from the Michael J. Fox Foundation, will be enrolling 400 recently diagnosed patients with Parkinson's and 200 people who do not have the disease.

Northwestern Medicine's Parkinson's Disease and Movement Disorders Center in Chicago hope to enroll 20 people to contribute for two years, according to the foundation. Northwestern are one of 14 research sites in the U.S., and the only one in the Midwest contribute in the study. Researchers will be seemed for the biomarkers for Parkinson's disease. "Parkinson's is a disease without a clear-cut diagnosis and without a cure," Dr. Tanya Simuni, principal examiner for the study at Northwestern and director of the Parkinson's Disease and group Disorders Center, said in a news release. "While significant strides have been made in the growth of drugs to manage the disease, hope for the prospect lies in the development of new drugs to slow or stop the progression of Parkinson's."

The four main symptoms of Parkinson's are tremor or trembling in the hands, arms, legs, jaw and face, stiffness of the limbs and trunk, slowness of group and impaired balance and coordination, according to the National Institute of Neurological Disorders and Stroke. Over time, people with Parkinson's have trouble walking, talking and responsibility simple tasks. Parkinson's typically influence people over age 50. Michael J. Fox was diagnosed with young-onset Parkinson's 19 years ago.

useful links : transport rankings

Idiopathic thrombocytopenic purpura

Idiopathic thrombocytopenic purpura (ITP) is the condition of having a short platelet count of no known cause. As most causes appear to be associated to antibodies against platelets, ITP is also recognized as immune thrombocytopenic purpura or immune-mediated thrombocytopenic purpura. Often ITP is asymptomatic, however a very little platelet count can lead to visible symptoms, such as purpura, or more seriously, bleeding diathesis. In many cases, ITP's cause is not idiopathic but autoimmune, with antibodies beside platelets being detected in approximately 60 percent of patients. Most often these antibodies are against platelet covering glycoproteins IIb-IIIa or Ib-IX, and are of the IgG type. The famous Harrington Hollingsworth experiment recognized the immune pathogenesis of ITP.

The covering of platelets with IgG renders them liable to opsonization and phagocytosis by splenic macrophages. The IgG autoantibodies are also thought to injure megakaryocytes, the precursor cells to platelets, but this is thought to contribute only slightly to the reduce in platelet numbers. The stimulus for auto-antibody making in ITP is probably abnormal T cell activity Preliminary findings suggest that these T cells can be influenced by drugs that target B cells, such as rituximab. The diagnosis of ITP is a procedure of exclusion. First, the clinician has to determine that there are no blood abnormalities other than small platelet count, and no physical signs except for signs of bleeding. Then, the secondary reason should be excluded. Secondary causes could be leukemia, medications, lupus erythematosus, cirrhosis, HIV, hepatitis C, inborn causes, and others.

In approximately one percent of cases, autoimmune hemolytic anemia and ITP coexist, a state referred to as Evans syndrome. A platelet count below 20,000 is usually an indication for treatment. Patients with a count between 20,000 and 50,000 are usually estimated on a case-by-case basis, and, with rare exceptions, there is usually no need to treat patients with a count above 50,000. Hospitalization may be recommended in cases of very low counts, and is highly desirable if the patient presents with significant internal or mucocutaneous bleeding. A count below 10,000 is potentially a medical emergency, as the patient may be susceptible to subarachnoid or intracerebral hemorrhage as a result of moderate head trauma. In most cases, treatment will be administered under the way of a hematologist.

useful links : transport rankings

Trichinosis

Trichinosis is a food borne disease cause by a microscopic parasite. Anyone who eats undercooked meat of impure animals can develop trichinosis. Pork products are concerned more often than other meats. Animals such as pigs, dogs, cats, rats and many wild animals (including fox, wolf and polar bear) may port the parasite. When humans eat infected pork that has been rudely cooked, they become infected. Improperly cooked wild animal meat may also be in charge for infecting humans. Person-to-person spread does not occur.The symptoms regularly start with fever, muscle soreness, pain and swelling around the eyes.

Thirst, profuse sweating, chills, weakness and tiredness may develop. Chest pain may be skilled since the parasite may become imbedded in the diaphragm. The incubation period varies depending upon the number of vermin in the meat and the amount eaten. It can collection from five to 45 days but is usually 10 to 14 days. Partial immunity may expand from infection. A drug called mebendazole is use in treatment.The best prevention is to make sure that pork products are correctly cooked. The desirable temperature is at slightest 150 degrees Fahrenheit. Storing infected meat in a freezer with a temperature no top than -13 degrees Fahrenheit for 10 days will also destroy the parasite.

useful links: transport rankings

Hantavirus Infections

Hantaviruses are a type of virus establish in rodents in different parts of the world. In the U.S., human hantavirus infections were first recognized in the southwest in 1993. In recent years, sporadic cases have been found in several eastern states including New York. Studies have shown that mice are often infected and appear to be the basis of infection.

The virus is approved by rodents such as mice which are found throughout North America. Infected rodents shed the live virus in saliva, droppings and urine. Humans are impure when they inhale microscopic particles that enclose viruses from rodent urine or droppings. Insect bites and pets are not believed to play a role in hantavirus broadcast.

Typical symptom includes high fever, muscle aches, cough and headache. After several days, respiratory problems worsen rapidly. The lungs may fill with liquid and victims may die of respiratory failure or shock. Typically two to four weeks, but it may variety from a few days up to two months. There is no specific action for hantavirus. Physicians have been administering ribavarin, an antiviral drug, on an trial basis to suspected victims.

useful links: transport rankings

Lupus

The country has lined up a set of its finest soldiers to protect the land. Although they may have faltered in the past, any enemy they have come across they have occupied. They begin to fire reverse at their own. This is the exact idea behind the autoimmune disease Lupus. Lupus is an autoimmune disease, which forces the body’s natural guard; the immune system, to attack the the internal tissues. When this occurs, it forces internal irritation and swelling of the damaged tissue.

Initially, an individual who suffers from Lupus, will experience inflammation inside. If the Lupus evolves into a harsh form, it can cause problems with the heart, lungs, nervous system, or the blood system. Although the correct cause of Lupus is unknown, scientists do have a wide range of theories. The two most notable theories are that Lupus is triggered by a viral disease or through hereditary lines. When an individual first contracts Lupus, they will experience combined pain, a skin rash, or a fever.

Once the symptoms decline, an individual becomes susceptible to more severe symptoms, such as organ problems. Since Lupus, produces a broad range of symptoms; there are some different remedies. If the individual experiences a skin rash, a doctor will set a corticosteroid cream; in the event of joint pain, and individual will be prescribed non-steroidal anti-inflammatory drugs, and if the person feels an irresistible sense of fatigue, a doctor will take antimalarial medicines.

useful links: transport rankings

breast cancer

Breast cancer is one of the mainly common cancers among women in New York State. Each year, about 13,900 women are diagnose with breast cancer and about 2,900 women die from the disease in New York State. It is estimated that one in eight women will expand breast cancer sometime during her life. Men also get breast cancer, but it is extremely rare. About 150 men are diagnose with breast cancer every year in New York State.

Breast cancer is more ordinary among older women. The risk for receiving breast cancer increases with age. More than three-quarters of women who find breast cancer are over the age of fifty. White women are more likely to get breast cancer than Black women. Also, women with high socioeconomic rank are more likely to get breast cancer. Scientists believe this may be connected to having their first child at an older age, fewer pregnancies, diet and possibly other factors shared by women in higher income groups.

Most women who expand breast cancer have no risk factors. Among women with normal risk, breast cancer cannot be prevented. Mammograms, breast self-examination, and test of your breasts by your health care provider increase the chances that breast cancer will be diagnosed early. Among women who have advanced than average risk, certain drugs may be useful in preventing breast cancer. All women should discuss their risk and screening or avoidance options with their health care provider.

useful links: transport rankings

Drugmakers prod by FDA for Neglected Disease Drugs

Roche Holding AG, Johnson & Johnson and Biogen Idec Inc. are being urged by U.S. regulator to see if presented medicines may help neglected disorders, after an incentive plan failed to spark research on new therapies.The Food and Drug Administration is publishing a list of 235 treatments today that may have benefit in unusual disorders and already have marketing clearance for other uses.

Identifying “low-hanging fruit” may compel large drugmakers to look beyond common ailments with guaranteed consumer require, said Tim Cote, head of the agency’s Office of Orphan Product Development.The list includes Roche’s hepatitis drug Pegasys, J&J’s leukemia medicine Leustatin and Biogen Idec’s several sclerosis drug Avonex. Regulators need new tactics since an research two years ago to give priority review vouchers in exchange for new drugs for steamy diseases drew only one participant.

“Large pharmaceutical companies are not as hard as we’d like to see them be,” Cote said in a phone interview. “I myself have knock on the doors of all the big boys.”About 30 million Americans have one of 7,000 rare diseases, define by the FDA as conditions alarming fewer than 200,000 people in the U.S. Medicines developed to treat these situation are called orphan drugs, under policy that encourage their growth.

useful links: transport rankings

Nigeria: Uncertainty of HIV/Aids Local medication

Lagos — Since the discovery of the Human Immuno Deficiency Virus (HIV) which causes Acquired Immuno Deficiency Syndrome (AIDS) 27 years ago, the world has been confronted with the penalty posed by the reality that no cure has been found against the disease.Again, no vaccine approved by the World Health Organisation (WHO) has been invented, thereby extending the hope for stable eradication of the virus.

Even the ARV drugs used in the management of People Living with HIV/AIDS (PLWHA) is in short supply in poor countries, as some giver nations to developing countries have soft-pedaled in their funding activities, partly due to the global financial recession, and distraction of funds meant for HIV/AIDS medication into private pockets of some corrupt government officials.

Whereas the developed nations have what it takes to provide for their PLWHAS, the poor countries still depend on drugs from outside donors to take care of theirs.In the quest to limit the spread of the virus, scientists in advanced countries are busy struggling to discover reliable vaccines, while traditional and orthodox healers in some developing nations like Nigeria are parading range of medications which they claim to be potent for HIV cure, even AIDS.

useful links: transport rankings